Proton Therapy
Radiation Therapy
Radiation Oncology

Dr. Pranshu Mohindra is Vice Chair, Operations and Quality, Department of Radiation Oncology at UH Cleveland Medical Center. He is also the Director of the Proton Therapy Center at University Hospitals. He works alongside thoracic surgeons and medical oncologists who also specialize in mesothelioma treatment.

In 2014, Dr. Mohindra was the lead radiologist at the University of Maryland School of Medicine. There he worked alongside several mesothelioma doctors including surgeon Dr. Joseph Friedberg and oncologist Dr. Christian Rolfo. There he helped researchers develop novel treatments for cancer patients.

Experience with the Latest Techniques

Mohindra is experienced in the latest radiation modalities.

His expertise includes the novel pencil-beam scanning proton therapy, intensity modulated proton therapy, intensity modulated radiation therapy, stereotactic body radiation therapy, stereotactic radiotherapy and image-guided brachytherapy.

He played a leading role in the initiation of his department’s MRI-guided brachytherapy program and is one of the few providers in the Washington, D.C., and Baltimore area with expertise in the brachytherapy procedures.

Proton therapy is a newer, precise form of radiation that treats a wide variety of solid tumors but is available only at select cancer centers around the country.

“Proton therapy can better spare healthy tissue, which minimizes side effects and can help patients significantly,” he said.

His radiation oncology training included residencies at the University of Wisconsin and the Tata Memorial Centre in Mumbai, India.

Mohindra did one fellowship in head and neck cancers at Princess Margaret Hospital in Toronto, and another in global academic research at the University of Texas MD Anderson Cancer Center.

Leader of NHI-Sponsored Clinical Trials

Mohindra is heavily involved in early-stage clinical trials that study the latest radiation therapies.

He is the principal investigator of two National Cancer Institute-sponsored clinical trials, including one studying brain metastases from non-small cell lung cancer.

The University of Maryland nominated him for the Board of Directors at the Alliance for Clinical Trials in Oncology, which covers almost 10,000 cancer specialists at medical centers and hospitals across the United States and Canada.

As associate professor at the University of Maryland, he was the director of research internships and mentored several medical students who won national awards for research projects.